5.7(top 5%)
impact factor
1.9K(top 10%)
76.6K(top 5%)
130(top 5%)
5.8(top 5%)
extended IF
all documents
doc citations
208(top 5%)

Top Articles

1Myeloid-Derived Suppressor CellsCancer Immunology Research20171,345
2PD-L1 Expression in Triple-Negative Breast CancerCancer Immunology Research2014994
3NF-κB, an Active Player in Human CancersCancer Immunology Research2014913
4Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T CellsCancer Immunology Research2013726
5Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid MalignanciesCancer Immunology Research2014711
6Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene SignaturesCancer Immunology Research2019691
7The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential SynergiesCancer Immunology Research2015631
8An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung CancerCancer Immunology Research2013599
9Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor AntigenCancer Immunology Research2015520
10In VitroCharacterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, andIn VivoToxicology in Non-Human PrimatesCancer Immunology Research2014514
11Bevacizumab plus Ipilimumab in Patients with Metastatic MelanomaCancer Immunology Research2014512
12NKG2D Receptor and Its Ligands in Host DefenseCancer Immunology Research2015508
13T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in HumansCancer Immunology Research2013489
14Tumors: Wounds That Do Not Heal—ReduxCancer Immunology Research2015465
15T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B CellsCancer Immunology Research2016456
16Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe ToxicityCancer Immunology Research2014448
17Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 BlockadeCancer Immunology Research2016428
18Chemokines in CancerCancer Immunology Research2014417
19Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune RegulationCancer Immunology Research2014408
20The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive forIn VivoAntitumor ActivityCancer Immunology Research2015406
21Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLCCancer Immunology Research2017400
22Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor CellsCancer Immunology Research2015391
23Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic CarcinomaCancer Immunology Research2015387
24Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer TherapiesCancer Immunology Research2015387
25Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic CellsCancer Immunology Research2015381
26Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor HypoxiaCancer Immunology Research2017381
27Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer PatientsCancer Immunology Research2017354
28HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 BlockadeCancer Immunology Research2015342
29Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent ModelCancer Immunology Research2016339
30PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall SurvivalCancer Immunology Research2013333
31The Immunological SynapseCancer Immunology Research2014330
32PD-1 Restrains Radiotherapy-Induced Abscopal EffectCancer Immunology Research2015327
33Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 BlockadeCancer Immunology Research2014322
34PD-1 Blockade Expands Intratumoral Memory T CellsCancer Immunology Research2016321
35Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug DiscoveryCancer Immunology Research2017321
36Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal AntibodyCancer Immunology Research2015314
37PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast CancerCancer Immunology Research2015310
38Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast CancerCancer Immunology Research2017309
39Oncolytic Viruses and Their Application to Cancer ImmunotherapyCancer Immunology Research2014308
40T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy SelectionCancer Immunology Research2018297
41Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder CancerCancer Immunology Research2016293
42Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human TissuesCancer Immunology Research2015292
43The Complex Role of Neutrophils in Tumor Angiogenesis and MetastasisCancer Immunology Research2016290
44Inflammasomes and CancerCancer Immunology Research2017290
45Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory ReceptorsCancer Immunology Research2015285
46Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In VivoCancer Immunology Research2013284
47Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint BlockadeCancer Immunology Research2017284
48The Biology and Medical Implications of Interleukin-6Cancer Immunology Research2014283
49Tim-3: An Emerging Target in the Cancer Immunotherapy LandscapeCancer Immunology Research2014278
50CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-HelpfulCancer Immunology Research2014276